Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

BACKGROUND: HER2-positive breast cancer occurs in 15–20% of breast cancer patients and is characterized by poor prognosis. Trastuzumab is considered the key drug for treatment of HER2-positive breast cancer patients. It improves patient survival; however, resistance to trastuzumab remains a challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakaria, Nermine H., Hashad, Doaa, Saied, Marwa H., Hegazy, Neamat, Elkayal, Alyaa, Tayae, Eman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193616/
https://www.ncbi.nlm.nih.gov/pubmed/37202799
http://dx.doi.org/10.1186/s40246-023-00493-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193616/
https://www.ncbi.nlm.nih.gov/pubmed/37202799
http://dx.doi.org/10.1186/s40246-023-00493-5

Ejemplares similares